As of September 30, 2026, Evolent Health, Inc carries a market capitalization of 394.58M, placing it among publicly traded companies globally. Its enterprise value stands at 1.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 394.58M |
| Enterprise Value | 1.22B |
Evolent Health, Inc's next confirmed earnings release is scheduled for February 24, 2027.
| Earnings Date | 2/24/2027 |
As of September 30, 2026, Evolent Health, Inc has 113.06M shares outstanding.
| Shares Outstanding | 113.06M |
These figures are as of September 30, 2026. The price-to-sales ratio is 0.17, and the price-to-book ratio stands at 1.06.
| PS Ratio | 0.17 |
| PB Ratio | 1.06 |
| P/TBV Ratio | -0.46 |
| P/FCF Ratio | 10.69 |
| P/OCF Ratio | 6.04 |
These figures are as of September 30, 2026. The EV/Sales ratio of 0.52 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.22B versus a market cap of 394.58M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 0.52 |
As of September 30, 2026, Evolent Health, Inc maintains a current ratio of 1.26, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 260.98, indicating elevated leverage, while an interest coverage ratio of -4.74 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.26 |
| Quick Ratio | 1.21 |
| Debt / Equity | 260.98 |
| Debt / EBITDA | -2.99 |
| Interest Coverage | -4.74 |
Over the twelve months ended September 30, 2026, Evolent Health, Inc posted a negative return on equity (ROE) of -83.57, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -23.00, reflecting losses generated across the asset base. The company generates approximately 557,821.90 in revenue per employee across its workforce of 4,200.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -83.57 |
| Return on Assets (ROA) | -23.00 |
| Revenue Per Employee | 557,821.90 |
| Employee Count | 4,200.00 |
Over the twelve months ended September 30, 2026, Evolent Health, Inc recorded 3.07M in income tax expense. The company reported a pretax loss of -504.63M and -507.69M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 3.07M |
As of the close on November 16, 2026, Evolent Health, Inc's stock has gained approximately 15.55% over the past 52 weeks. The 50-day moving average sits at 4.23, while the 200-day moving average is 3.93.
| 52-Week Price Change | 15.55% |
| 50-Day Moving Average | 4.23 |
| 200-Day Moving Average | 3.93 |
Over the twelve months ended September 30, 2026, Evolent Health, Inc generated 2.34B in revenue and converted that into -507.69M in net income, yielding earnings per share of -4.52. EBITDA reached -324.93M, while operating income came in at -46.79M.
| Revenue | 2.34B |
| Gross Profit | 350.28M |
| Operating Income | -46.79M |
| Pretax Income | -504.63M |
| Net Income | -507.69M |
| EBITDA | -324.93M |
| EBIT | -434.58M |
| Earnings Per Share (EPS) | -4.52 |
As of September 30, 2026, Evolent Health, Inc holds 148.26M in cash and equivalents against 973.05M in total debt, resulting in a net debt position of 821.23M. Total book value stands at 372.85M, with working capital of 127.18M providing operational flexibility.
| Cash & Cash Equivalents | 148.26M |
| Total Debt | 973.05M |
| Net Debt | 821.23M |
| Equity (Book Value) | 372.85M |
| Book Value Per Share | 3.30 |
| Working Capital | 127.18M |
Evolent Health, Inc produced 64.88M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -28.22M in capital expenditures, free cash flow totaled 36.66M - equivalent to 0.33 per share.
| Operating Cash Flow | 64.88M |
| Capital Expenditures | -28.22M |
| Free Cash Flow | 36.66M |
| FCF Per Share | 0.33 |
Over the twelve months ended September 30, 2026, Evolent Health, Inc posted a gross margin of 14.95, reflecting its pricing power and cost economics. The operating margin of -2.00 and net profit margin of -21.67 provide insight into operational efficiency.
| Gross Margin | 14.95 |
| Operating Margin | -2.00 |
| Pretax Margin | -21.54 |
| Profit Margin | -21.67 |
| EBITDA Margin | -13.87 |
Over the twelve months ended September 30, 2026, Evolent Health, Inc paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 9.35, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 28.52, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Evolent Health, Inc shareholders.
| Shareholder Yield | 28.52 |
| FCF Yield | 9.35 |
As of September 30, 2026, Evolent Health, Inc has an Altman Z-Score of 0.68, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.68 |